Please login to the form below

Not currently logged in
Email:
Password:

acalabrutinib

This page shows the latest acalabrutinib news and features for those working in and with pharma, biotech and healthcare.

Cancer drugs and China sustain AZ’s return to growth

Cancer drugs and China sustain AZ’s return to growth

BTK inhibitor Calquence (acalabrutinib) – a rival to Johnson/AbbVie's big-selling Imbruvica (ibrutinib) – could be filed for chronic lymphocytic leukaemia (CLL) before year-end extending its current use in mantle

Latest news

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics